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CyclodextrinesAbstract Fluoxetine is an antidepressant, a selective serotonin reuptake inhibitor (SSRI) used pri-
marily in the treatment of major depression, panic disorder and obsessive compulsive disorder. Chi-
ral separation of racemic ﬂuoxetine is necessary due to its enantioselective metabolism. In order to
develop a suitable method for chiral separation of ﬂuoxetine, cyclodextrin (CD) modiﬁed capillary
electrophoresis (CE) was employed. A large number of native and derivatized, neutral and ionized
CD derivatives were screened to ﬁnd the optimal chiral selector. As a result of this process, heptakis
(2,3,6-tri-O-methyl)-b-CD (TRIMEB) was selected for enantiomeric discrimination. A factorial
analysis study was performed by orthogonal experimental design in which several factors are varied
at the same time to optimize the separation method. The optimized method (50 mM phosphate buf-
fer, pH = 5.0, 10 mM TRIMEB, 15 C, + 20 kV, 50 mbar/1 s, detection at 230 nm) was successful
for baseline separation of ﬂuoxetine enantiomers within 5 min. Our method was validated according
to ICH guidelines and proved to be sensitive, linear, accurate and precise for the chiral separation of
ﬂuoxetine.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fluoxetine ((±)-N-methyl-3-phenyl-3-[4-(triﬂuoromethyl)phe
noxy]propan-1-amine) (Fig. 1) is a widely marketed selective
serotonin (5-hydroxytryptamine) reuptake inhibitor (SSRI)
used in the treatment major depressive disorder, obsessive-
compulsive disorder, panic disorder, bulimia nervosa and pre-
menstrual dysphoric disorder (Cheer and Goa, 2001).phoresis.
Figure 1 Fluoxetine chemical structure (* denotes the chiral
center).
2 M. Caˆrcu-Dobrin et al.Fluoxetine has a chiral center in its structure resulting into
the existence of two enantiomers, R-ﬂuoxetine and S-
ﬂuoxetine.
The two enantiomers of ﬂuoxetine are similarly effective in
blocking serotonin reuptake. However these enantiomers are
metabolized differently. Fluoxetine is extensively metabolized
by cytochrome P450 enzyme system through demethylation
into the active chiral metabolite norﬂuoxetine, allowing a more
prolonged biological action of the drug. R-ﬂuoxetine and S-
ﬂuoxetine have different metabolic rates, as the clearance of
R-ﬂuoxetine is about four times greater than the one of S-
ﬂuoxetine; these differences translate into differences in half-
life, the half-life of S-ﬂuoxetine being one quarter than that
of R-ﬂuoxetine. In the case of norﬂuoxetine only the S-
enantiomer has similar potency as the parent drug (Brosen,
1998; Sproule et al., 1997).
The use of R-enantiomer was expected to result in less vari-
able plasma levels of ﬂuoxetine and its active metabolites com-
pared to those observed with racemic ﬂuoxetine, but the
clinical development of R-ﬂuoxetine for the treatment of
depression was stopped because of a small but statistically sig-
niﬁcant prolongation of the QT interval with high doses
(McConathy and Owens, 2003).
Taking into consideration the aspects presented above the
elaboration of new methods for the enantioseparation of ﬂuox-
etine represents a necessity and also a challenge.
Capillary electrophoresis (CE) has become an interesting
alternative, but also complementary to the more frequently
used high performance liquid chromatographic (HPLC) meth-
ods, with advantages related to the low solvent and analyte
consumption, short analysis time, rapid method development
and high selectivity. Enantioseparations by CE are achieved
by direct addition of chiral selectors, into the background elec-
trolyte (BGE); as the enantioseparation takes place due to the
different non-covalent molecular interaction of the enan-
tiomers with a chiral selector, whose electrophoretic mobility
is different to that of the enantiomers (Amini, 2011;
Chankvetadze, 2007).
The most frequently additives used are cyclodextrins (CDs)
because they are commercially available, UV-transparent and
relatively low cost. CDs can form complexes with molecules
based on their inclusion into the hydrophobic cavity; sec-
ondary interactions may include hydrogen bonding or
dipole–dipole interactions with the hydroxyl groups on the
CDs, or with other polar substituents of the CDs (Rezanka
et al., 2014).
In chiral CE the host-guest complexation between the CD
and the enantiomers is responsible for the enantioresolution
and the electrophoresis and electroosmosis permit differen-
tial migrations of the host-guest complexes (Dubsky et al.,
2010).Please cite this article in press as: Caˆrcu-Dobrin, M. et al., Enantioselective analysis
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etine are mainly HPLC methods with UV (Gatti et al., 2003),
ﬂuorescence (Guo et al., 2003) or mass spectrometry
(Sutherland et al., 2001) detection; enantioseparation being
done using indirect methods such as derivatization (Guo
et al., 2003) and direct methods using CDs (Yu et al., 2002)
or chiral stationary phases (Yu et al., 2006).
Few reports on the application of CE methods for separa-
tion of ﬂuoxetine enantiomers were found in the literature.
These methods present usually the enantioseparation in acidic
condition using negatively charged CDs or combined neutral
and negatively charged CDs. A systematic approach to enan-
tiomeric separations in CE and HPLC with chiral mobile
phase additives or a chiral stationary phase was described in
a study of ﬂuoxetine and norﬂuoxetine with CDs as chiral
selectors (Piperaki et al., 1995). High detection sensitivity CE
was used for the stereoselective analysis of ﬂuoxetine and nor-
ﬂuoxetine in plasma and serum samples using a CD-modiﬁed
phosphate buffer at pH 2.5 and a dual CD system containing
dimethylated-b and phosphated-c-CDs (Desiderio et al., 1999).
A complex screening including 11 neutral and charged CDs
was carried out for the enantioseparation of ﬂuoxetine and
four of its structural analogs; several negatively charged CDs
showed enantioresolution abilities at pH 2.5 due to the high
electrophoretic mobility of these CDs in the opposite direction
to ﬂuoxetine as well as due to the enhanced binding with pos-
itively charged ﬂuoxetine (Inoue and Chang, 2003). In order to
prevent the absorption of the basic compound ﬂuoxetine on
the negatively charged capillary wall in low pH buffer and to
improve enantioresolution, guanidine as cationic additive can
be added to a phosphate buffer containing sulfobuthylether-
b-CD at pH 2.5 (Javid et al., 2013). An electrokinetic chro-
matography–counter current procedure for the separation of
ﬂuoxetine enantiomers using a phosphate buffer at pH 8.0
and highly sulfated b-CD was developed and applied to the
determination of the enantiomers in pharmaceutical formula-
tions (Asensi-Bernardi et al., 2013). Sulfated maltodextrin as
a novel anionic chiral selector was used as an alternative to
CDs for the separation of several basic drugs including ﬂuox-
etine (Tabani et al., 2015).
The aim of the study was the development of a new, simple
and rapid alternative method for the chiral separation of ﬂuox-
etine enantiomers using a CZE method and CD as chiral selec-
tors; and also the optimization of analytical conditions and
validation of the newly developed method according to ICH
guidelines. For the optimization process we used an experi-
mental design approach, a methodology of experimental
research in which the variables under study are simultaneously
changed inside an experiment; these strategy being aimed to
guide the researcher in selecting regions of interest inside a
large experimental region, with a minimum number of experi-
ments (Orlandini et al., 2014).
2. Materials and methods
2.1. Chemicals and reagents
R,S-ﬂuoxetine and S-ﬂuoxetine of pharmaceutical grade were
acquired from Solmag (Mulazzano, Italy). Phosphoric acid
(85%), disodium hydrogenophosphate, and sodium dihy-
drogenophosphate were purchased from Merck (Darmstadt,of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis.
Enantioselective analysis of ﬂuoxetine in pharmaceutical formulations 3Germany), and sodium hydroxide was from Lach Ner (Nera-
tovice, Czech Republic). Deionized water was produced by a
Milli-Q system (Millipore, USA). All reagents were of analyt-
ical grade.
The following CDs were used as chiral additives: native
neutral CDs (b-CD, c-CD), derivatized neutral CDs
(hydroxypropyl-b-CD – HP-b-CD, randomly methylated
b-CD – RAMEB, heptakis (2,6-di-O-methyl)-b-CD - DIMEB,
heptakis(2,3,6-tri-O-methyl)- b-CD - TRIMEB), derivatized
ionizable CDs (carboxymethyl-b-CD - CM-b-CD,
sulfobuthylether-b-CD SBE-b-CD). All CDs were obtained
from Cyclolab (Budapest, Hungary) with the exception of
SBE-b-CD – (Capsitol) which was obtained from Cydex
Corp. (USA).
For the determination from pharmaceutical products, Pro-
zac (Eli Lilly, USA) and Fluoxin (VimSpectrum, Romania)
capsules containing 20 mg ﬂuoxetine were used. The pharma-
ceutical preparations were purchased from a local pharmacy.
2.2. Instrumentation
All experiments were carried out on an Agilent 1600 CE sys-
tem (Agilent Technologies, Waldbronn, Germany) equipped
with a diode array UV detector. Separations were performed
on an uncoated fused-silica capillary with a total length of
48 cm (40 cm effective length), having an internal diameter of
50 um (Agilent, Germany). The electropherograms were
recorded and processed by Chemstation 7.01 software (Agi-
lent, Germany). Buffer pH was determined using a Terminal
740 pH–meter (Inolab, Germany).
2.3. Electrophoretic conditions
The capillary was conditioned with 0.1 M NaOH for 30 min,
puriﬁed water for 15 min and BGE for 15 min. Between runs,
the capillary was preconditioned with 0.1 M NaOH, puriﬁed
water and buffer electrolyte, each for 2 min.
BGE solutions were prepared dissolving the appropriate
amount of buffer constituents in ultrapure water and adjusting
the pH if necessary with 1 M phosphoric acid or 1 M NaOH.
Stock solutions containing 1 mg mL1 of the racemic ﬂuox-
etine were prepared in methanol, and diluted prior to use with
the same solvent to the appropriate concentration.
Both BGE and sample solutions were ﬁltered through a
0.45 lm pore size membrane ﬁlter and degassed in an ultra-
sonic bath for 5 min prior to use. All solutions were kept in
the refrigerator when not in use.
Samples and standards were injected by hydrodynamic
injection (50 mbar for 1 s) at the anodic end of the capillary.
The initial electrophoretic conditions were the following: volt-
age +20 kV, capillary temperature 25 C, detector wavelength
230 nm, sample concentration 25 lg mL1.
2.4. Pharmaceutical sample preparation
The content of ten capsules was weighed, ground and mixed in
a mortar. Appropriate amount of the powder (equivalent to
20 mg of racemic ﬂuoxetine) was taken and dissolved in
10 mL methanol, sonicated in a ultrasonic water bath for
5 min and then diluted to 100 mL with methanol in a volumet-
ric ﬂask. The solutions were further diluted with methanol toPlease cite this article in press as: Caˆrcu-Dobrin, M. et al., Enantioselective analysis
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CE system for the separation.
3. Results and discussions
3.1. Preliminary analysis
Fluoxetine is a basic analyte containing tertiary amine nitro-
gen, with a pKa value of 9.80, and consequently is positively
charged over a relatively large range of pH (acidic and neutral
pHs).
In order to establish the electrophoretic behavior of the
analyte in an achiral system, different phosphate BGEs in a
pH range between 2.5 and 11.0 were used, in a 25 mM concen-
tration. Fluoxetine can be detected over a pH range between
2.5 and 7.0.
Initial electrophoretic separations were performed at three
pH levels: 2.5, 5.0 and 7.0. During the CD screening process,
initial concentration of 10 mM neutral CDs was added to
the buffer solution, while for charged CDs we added a concen-
tration of 5 mM in order to limit the increase in ionic strength
which generated high currents and subsequent peak
broadening.
The only CD that exhibited chiral interactions with ﬂuox-
etine was TRIMEB, a derivatized neutral CD. The best results
were obtained when using a phosphate buffer at pH 5.0.
The results were evaluated in terms of separation factors (a)
calculated as the ratio of the migration times of the optical iso-
mers, and resolution (Rs) obtained by the Rs = 2(t2  t1)/
(w1 + w2) equation, where the migration times (t1 and t2)
and the peak-widths (w1 and w2) were marked for the slow
and fast migrating enantiomers, respectively.
3.2. Optimization of the analytical conditions
In order to improve the separation resolution of the enan-
tiomers, an optimization of the developed method is crucial.
Conventional method optimization is based on changing
one variable at a time, while keeping the other variables con-
stant; this meticulous approach is the so-called ‘‘one-factor-a
t-a-time” approach, and involves a large number of individual
experiments and consumes a long time; therefore, the simulta-
neous variation of several factors has recently become wide-
spread (Hanrahan et al., 2008).
The multivariate approach usually leads to optimal condi-
tions in a relatively reduced number of experimental runs
and offers more comprehensive information on the separation
system, making possible to detect also possible interactions
between the studied factors.
Orthogonal experimental designs provide a simple and efﬁ-
cient way to screen a large number of factors in a reduced
number of experimental runs in order to differentiate between
signiﬁcant and less important experimental variables
(Orlandini et al., 2014).
In order to optimize the chiral separation of ﬂuoxetine, an
L18 (6
3) orthogonal array table was employed, where 18 is the
total number of experiments, which results from the variation
of 6 experimental factors at 3 different levels. The factors
selected for optimization were the following: BGE concentra-
tion (25, 50, 100 mM), BGE pH (4.5, 5.0, 5.5), CD concentra-
tion (5, 10, 15 mM), applied voltage (15, 20, 25 kV),of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis.
Table 1 Orthogonal experimental design table for chiral method optimization with corresponding resolution values.
Experiment BGE conc. [mM] BGE pH CD conc. [mM] Voltage [kV] Temperature [C] Injection parameters Rs
1 25 4.5 5 15 15 50 mbar  1 s 1.05
2 50 5.0 10 20 15 30 mbar  5 s 1.80
3 100 5.5 15 25 15 50 mbar  3 s 1.62
4 50 5.5 5 15 20 30 mbar  5 s 1.24
5 100 4.5 10 20 20 50 mbar  3 s 1.20
6 25 5.0 15 25 20 50 mbar  1 s 1.48
7 100 5.0 10 15 25 50 mbar  1 s 1.28
8 25 5.5 15 20 25 30 mbar  5 s 1.25
9 50 4.5 5 25 25 50 mbar  3 s 1.01
10 50 5.0 15 15 15 50 mbar  3 s 1.77
11 100 5.5 5 20 15 50 mbar  1 s 1.30
12 25 4.5 10 25 15 30 mbar  5 s 1.23
13 25 5.5 10 15 20 50 mbar  3 s 1.20
14 50 4.5 15 20 20 50 mbar  1 s 1.37
15 100 5.0 5 25 20 30 mbar  5 s 1.54
16 100 4.5 15 15 25 30 mbar  5 s 1.09
17 25 5.0 5 20 25 50 mbar  3 s 1.32
18 50 5.5 10 25 25 50 mbar  1 s 1.30
Q1 1.26 1.15 1.24 1.27 1.46 1.29
Q2 1.41 1.51 1.43 1.37 1.33 1.35
Q3 1.33 1.31 1.33 1.36 1.20 1.35
R 0.15 0.36 0.19 0.09 0.26 0.06
Q1–Q3: the average resolution value under every level of the variable (Q1 – low level; Q2 – medium level; Q3 – high level).
R: range value, the difference between the maximal and minimal value of the three levels for each parameter.
Figure 2 Chiral separation of ﬂuoxetine enantiomers in optimized conditions (experimental conditions: 50 mM phosphate, pH = 5.0,
10 mM TRIMEB, temperature 15 C, voltage +20 kV, hydrodynamic injection 50 mbar/1 s, UV detection 230 nm).
Table 2 Intra-day and inter-day reproducibility data for repeated injections of different concentrations of racemic ﬂuoxetine
standard.
Factor conc. (lg mL1) Relative standard deviation - RSD (%)
Migration time (min) Peak areas
R-ﬂuoxetine S-ﬂuoxetine R-ﬂuoxetine S-ﬂuoxetine
Intra-day precision (n = 6)
10 0.03 0.03 0.57 0.64
25 0.07 0.08 0.74 0.82
50 0.14 0.16 0.75 0.83
Inter-day precision (n = 18)
10 0.40 0.45 1.27 1.50
25 0.35 0.40 1.18 1.40
50 0.42 0.48 1.20 1.32
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Table 3 Calibration data and LOD/LOQ values for ﬂuoxetine chiral separation (concentration range = concentration range: 2.5–
50 lg mL1, n= 3).
Enantiomers Regression equation Correlation coeﬃcient LOD (lg mL1) LOQ (lg mL1)
R-ﬂuoxetine y= 0.6525x+ 2.1230 0.995 1.69 5.63
S-ﬂuoxetine y= 0.6679x+ 1.9803 0.994 1.77 5.9
Table 4 Recovery values obtained from the determination of
ﬂuoxetine spiked with different levels of standards.
Racemic ﬂuoxetine (lg mL1) Mean recovery (% ±SD)
R-ﬂuoxetine S-ﬂuoxetine
10 98.62 ± 2.41 98.73 ± 2.63
25 99.31 ± 2.70 97.12 ± 1.91
50 99.23 ± 2.42 98,44 ± 2.34
Enantioselective analysis of ﬂuoxetine in pharmaceutical formulations 5temperature (15, 20, 25 C), injection parameters
(50 mbar  1 s, 50 mbar  3 s, 30 mbar  5 s). As response
factor, resolution values were recorded in each experiment.Figure 3 Chiral separation of ﬂuoxetine enantiomers from pharmace
50 mM phosphate, pH = 5.0, 10 mM TRIMEB, temperature 15 C, vo
230 nm).
Please cite this article in press as: Caˆrcu-Dobrin, M. et al., Enantioselective analysis
Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.09.007The rank order of the studied variables was as follows: BGE
pH, capillary temperature, CD concentration, BGE concentra-
tion, applied voltage, injection parameters (Table 1).
Since baseline resolution was achieved and variance analy-
sis (ANOVA) of the experimental results revealed that none of
the investigated parameters had individually signiﬁcant effect
on resolution values in the investigated range, further opti-
mization was not necessary.
The pH of the BGE plays an important role in determining
the extent of ionization of the analyte in the separation pro-
cess, affecting the electrophoretic mobility of the substance
and also the magnitude of EOF.
An increase in the ionic strength of the BGE will generate
longer migration time due to slower EOF as well as theutical preparations Prozac and Fluoxin (experimental conditions:
ltage +20 kV, hydrodynamic injection 50 mbar/1 s, UV detection
of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis.
Table 5 Determination of ﬂuoxetine enantiomers from pharmaceutical preparations.
Pharmaceutical product Declared enantiomer quantity (mg) Found enantiomer quantity (mg) ± SD (n= 3)
R-ﬂuoxetine S-ﬂuoxetine R-ﬂuoxetine S-ﬂuoxetine
Prozac (20 mg ﬂuoxetine) 10 10 10.1 ± 0.35 9.9 ± 0.32
Fluoxin (20 mg ﬂuoxetine) 10 10 10.15 ± 0.31 9.85 ± 0.24
6 M. Caˆrcu-Dobrin et al.reduction in electrophoretic mobility of the ionic analyte.
Working with high ionic strength buffers leads to better chiral
resolution but on the other hand at certain concentration the
heat dissipation ability of the separation system will be
exceeded.
Increasing the voltage results in shorter migration times,
but generation of Joule heat affects resolution and efﬁciency
when the voltage is increased.
As the temperature increases, both analysis time and chiral
resolution decrease, due to lower viscosity of the BGE.
By increasing injection time, the sensitivity increases, but
the chiral resolution decreases due to peak broadening.
Based on the results of the experimental design, the optimal
resolution would be achieved with a BGE consisting of 50 mM
phosphate, pH = 5.0, 10 mM TRIMEB as chiral selector, at a
temperature of 15 C, voltage +20 kV, injection parameters
50 mbar/1 s. Adopting these optimized conditions, baseline
enantiomeric separation of ﬂuoxetine was achieved, with a
Rs value of 1.90 and a of 1.04 (Fig. 2).
The migration order of the two enantiomers was deter-
mined by spiking the sample solution with the stock solution
of the pure S-enantiomer. The ﬁrst peak to pass the detector
window was determined to be R-ﬂuoxetine followed by S-
ﬂuoxetine.
3.3. Analytical performance
The developed method was validated, in terms of repeatability,
precision, linearity, sensitivity (limit of detection and limit of
quantiﬁcation) and accuracy.
Intra-day precision was assessed by injecting racemic ﬂuox-
etine standards at three different concentrations (10, 25, and
50 lg mL1) six times on the same day. Moreover, the inter-
day precision was veriﬁed by introducing three different con-
centrations of the standard (10, 25, and 50 lg mL1) six times
for three consecutive days (Table 2).
Calibration plots were constructed by preparing standard
solutions (n= 3) at six concentrations in a speciﬁc concentra-
tion range (concentration range: 2.5–50 lg mL1) (Table 3).
The limit of detection (LOD) and quantiﬁcation (LOQ)
were estimated as standard deviation of regression equation/
slope of the regression equation multiplied by 3.3 and 10,
respectively (Table 3).
The accuracy of the method was veriﬁed through the recov-
ery test; as an appropriate amount of racemic ﬂuoxetine tablet
powder was weighed, dissolved in methanol and the solution
was spiked with known amount of the standard and each
was analyzed in triplicates (Table 4).
3.4. Analysis from pharmaceutical preparations
The optimized method was applied for the determination of
ﬂuoxetine enantiomers in original (Prozac) and generic (Flu-Please cite this article in press as: Caˆrcu-Dobrin, M. et al., Enantioselective analysis
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ment between the value claimed by the manufacturer and
that determined by the CE method was obtained (Table 5).
No interference from the drug formulation excipients could
be observed on the electropherogram. Fig. 3 shows typical
electropherograms of the pharmaceutical preparations.4. Conclusions
A simple, rapid and cost effective CZE method has been devel-
oped for the enantioselective determination of ﬂuoxetine
enantiomers.
The developed separation system was optimized by employ-
ing an orthogonal experimental design; the main advantages of
using multivariate approaches being the reduction in number
of experiments and statistical data processing in order to ﬁnd
optimal conditions.
In comparison with the HPLC chiral separation methods
described before (Guo et al., 2003; Yu et al., 2002) our method
has the advantages that it does not require derivatization,
expensive chiral columns or large amounts of solvents as
mobile phase.
Additionally if we compare our method with the CE meth-
ods previously published in the literature, our method uses
neutral derivatized CD (TRIMEB) instead of derivatized anio-
nic CD (Inoue and Chang, 2003; Asensi-Bernardi et al., 2013;
Javid et al., 2013) or dual CD systems (combination within a
neutral and a negatively charged CD) (Desiderio et al.,
1999), simple basic electrophoretic conditions offering also a
short analysis time (less than 5 min).
This research did not receive any speciﬁc grant from
funding agencies in the public, commercial, or not-for-proﬁt
sectors.References
Amini, A., 2011. Recent developments in chiral capillary electrophore-
sis and applications of this technique to pharmaceutical and
biomedical analysis. Electrophoresis 22, 3107–3130.
Asensi-Bernardi, L., Martin-Biosca, Y., Fornet-Herrero, E., Sagrado,
S., Medina Herna´ndez, M.J., 2013. Determination of ﬂuoxetine
enantiomers in pharmaceutical formulations by electrokinetic
chromatography–counter current technique. Biomed. Chromatogr.
27, 377–381.
Brosen, K., 1998. Differences in interactions of SSRIs. Int. Clin.
Psychopharmacol. 13, S45–47.
Chankvetadze, B., 2007. Enantioseparations by using capillary elec-
trophoretic techniques: the story of 20 and a few more years. J.
Chromatogr. A 1168, 45–70.
Cheer, S.M., Goa, K.L., 2001. Fluoxetine: a review of its therapeutic
potential in the treatment of depression associated with physical
illness. Drugs 6, 81–110.
Desiderio, C., Rudaz, S., Raggi, M.A., Fanali, S., 1999. Enantiomeric
separation of ﬂuoxetine and norﬂuoxetine in plasma and serumof fluoxetine in pharmaceutical formulations by capillary zone electrophoresis.
Enantioselective analysis of ﬂuoxetine in pharmaceutical formulations 7samples with high detection sensitivity capillary electrophoresis.
Electrophoresis 20, 3432–3438.
Dubsky, P., Svobodova, J., Tesarova, E., Gas, B., 2010. Enhanced
selectivity in CZE multi-chiral selector enantioseparation systems:
proposed separation mechanism. Electrophoresis 31, 1435–1441.
Gatti, G., Bonomi, I., Marchiselli, R., Fattore, C., Spina, E., Scordo,
G., Paciﬁci, R., Perucca, E., 2003. Improved enantioselective assay
for the determination of ﬂuoxetine and norﬂuoxetine enantiomers
in human plasma by liquid chromatography. J. Chromatogr. B 784,
375–383.
Guo, X., Fukushima, T., Li, F., Imai, K., 2003. Determination of
ﬂuoxetine and norﬂuoxetine in rat plasma by HPLC with pre-
column derivatization and ﬂuorescence detection. Biomed. Chro-
matogr. 17, 1–5.
Hanrahan, G., Montes, R., Gomez, F., 2008. Chemometric experi-
mental design based optimization techniques in capillary elec-
trophoresis. Anal. Bioanal. Chem. 390, 169–179.
Inoue, T., Chang, J.P., 2003. Chiral separation of ﬂuoxetine and its
analogs with charged cyclodextrins by capillary electrophoresis. J
Liq Chromatogr Rel Technol 26, 2351–2367.
Javid, F.S., Shafaati, A., Zarghi, A., 2013. Improvement of capillary
electrophoretic enantioseparation of ﬂuoxetine by a cationic
additive. Iran J Pharm Res 12, 71–76.
McConathy, J., Owens, M.J., 2003. Stereochemistry in drug action
primary care companion. J. Clin. Psychiatry 5, 70–73.
Orlandini, S., Gotti, R., Furlanetto, S., 2014. Multivariate optimiza-
tion of capillary electrophoresis methods: a critical review. J.
Pharm. Biomed. Anal. 87, 290–307.Please cite this article in press as: Caˆrcu-Dobrin, M. et al., Enantioselective analysis
Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.09.007Piperaki, S., Penn, S.G., Goodall, D.M., 1995. Systematic approach to
treatment of enantiomeric separations in capillary electrophoresis
and liquid chromatography II. A study of the enantiomeric
separation of ﬂuoxetine and norﬂuoxetine. J. Chromatogr. A 700,
59–67.
Rezanka, P., Navratilova, K., Rezanka, M., Kral, V., Sykora, D.,
2014. Application of cyclodextrins in chiral capillary electrophore-
sis. Electrophoresis 35, 2701–2721.
Sproule, B.A., Naranjo, C.A., Brenmer, K.E., Hassan, P.C., 1997.
Selective serotonin reuptake inhibitors and CNS drug interactions.
A critical review of the evidence. Clin. Pharmacokinet. 33, 454–471.
Sutherland, F.C., Badenhorst, D., de Jager, A.D., Scanes, T., Hundt,
H.K., Swart, K.J., Hundt, A.F., 2001. Sensitive liquid chromato-
graphic-tandem mass spectrometric method for the determination
of ﬂuoxetine and its primary active metabolite norﬂuoxetine in
human plasma. J. Chromatogr. A 914, 45–51.
Tabani, H., Mahyari, M., Sahragard, A., Fakhari, A.R., Shaabani, A.,
2015. Evaluation of sulfated maltodextrin as a novel anionic chiral
selector for the enantioseparation of basic chiral drugs by capillary
electrophoresis. Electrophoresis 36, 305–311.
Yu, H.W., Ching, C.B., Fu, P., Ng, S.C., 2002. Enantioseparation of
ﬂuoxetine on a new b-cyclodextrin bonded phase column by
HPLC. Sep. Sci. Technol. 37, 1401–1415.
Yu, L., Mei-Li, F., Jie-Guo, X., 2006. Enantiomeric separation of
ﬂuoxetine derivatives on polysaccharide-based chiral columns.
Arch. Pharm. 339, 461–465.of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis.
